BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, Weiss KH, Liaskou E, Vesterhus M, Karlsen TH, Mindorf S, Schemmer P, Bär F, Teegen B, Schröder T, Ehlers M, Hammers CM, Komorowski L, Lehnert H, Fellermann K, Derer S, Hov JR, Sina C. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut 2017;66:137-44. [PMID: 27406039 DOI: 10.1136/gutjnl-2016-311739] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
Number Citing Articles
1 Tornai T, Tornai D, Sipeki N, Tornai I, Alsulaimani R, Fechner K, Roggenbuck D, Norman GL, Veres G, Par G, Par A, Szalay F, Lakatos PL, Antal-Szalmas P, Papp M. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis. Sci Rep 2018;8:399. [PMID: 29321484 DOI: 10.1038/s41598-017-18622-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
2 Wu H, Chen C, Ziani S, Nelson LJ, Ávila MA, Nevzorova YA, Cubero FJ. Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells 2021;10:1107. [PMID: 34062960 DOI: 10.3390/cells10051107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Derer S, Brethack AK, Pietsch C, Jendrek ST, Nitzsche T, Bokemeyer A, Hov JR, Schäffler H, Bettenworth D, Grassl GA, Sina C. Inflammatory Bowel Disease-associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria. Inflamm Bowel Dis 2020;26:1856-68. [PMID: 32304568 DOI: 10.1093/ibd/izaa069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhang S, Luo J, Wu Z, Roggenbuck D, Schierack P, Reinhold D, Li J, Zeng X, Zhang F, Qian J, Li Y. Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease. Clin Transl Gastroenterol 2018;9:e133. [PMID: 29446764 DOI: 10.1038/ctg.2018.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ehlken H, Zenouzi R, Schramm C. Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance. Curr Opin Gastroenterol 2017;33:78-84. [PMID: 28146445 DOI: 10.1097/MOG.0000000000000335] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
6 Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67:1298-1323. [PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022] [Cited by in Crossref: 244] [Cited by in F6Publishing: 209] [Article Influence: 48.8] [Reference Citation Analysis]
7 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Reference Citation Analysis]
8 Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos DP, Mytilinaiou MG, Hammermann J, Laass MW, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P. Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype. Front Immunol 2018;9:1959. [PMID: 30233574 DOI: 10.3389/fimmu.2018.01959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
9 Lopens S, Krawczyk M, Papp M, Milkiewicz P, Schierack P, Liu Y, Wunsch E, Conrad K, Roggenbuck D. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia. Auto Immun Highlights 2020;11:6. [PMID: 32178720 DOI: 10.1186/s13317-020-00129-x] [Reference Citation Analysis]
10 Liwinski T, Heinemann M, Schramm C. The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts. Semin Immunopathol 2022. [PMID: 35536431 DOI: 10.1007/s00281-022-00936-6] [Reference Citation Analysis]
11 Aravalli RN, Steer CJ. Immune-Mediated Therapies for Liver Cancer. Genes (Basel) 2017;8:E76. [PMID: 28218682 DOI: 10.3390/genes8020076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
12 Loosen SH, Vucur M, Trautwein C, Roderburg C, Luedde T. Circulating Biomarkers for Cholangiocarcinoma. Dig Dis 2018;36:281-8. [PMID: 29807369 DOI: 10.1159/000488342] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
13 Cargill T, Culver EL. The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases. Front Immunol 2021;12:661196. [PMID: 33936097 DOI: 10.3389/fimmu.2021.661196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hohenester S, Beuers U. [Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults]. Internist (Berl) 2017;58:805-25. [PMID: 28721532 DOI: 10.1007/s00108-017-0287-z] [Reference Citation Analysis]
15 Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol. 2018;9:609. [PMID: 29636752 DOI: 10.3389/fimmu.2018.00609] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
16 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
17 Taylor SA, Assis DN, Mack CL. The Contribution of B Cells in Autoimmune Liver Diseases. Semin Liver Dis 2019;39:422-31. [PMID: 31226726 DOI: 10.1055/s-0039-1688751] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Wunsch E, Norman GL, Milkiewicz M, Krawczyk M, Bentow C, Shums Z, Mahler M, Lopens S, Reinhold D, Franke A, Schramm C, Roggenbuck D, Milkiewicz P. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther 2021;53:302-13. [PMID: 33159471 DOI: 10.1111/apt.16153] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Terziroli Beretta-piccoli B, Mieli-vergani G, Vergani D. The clinical usage and definition of autoantibodies in immune-mediated liver disease: A comprehensive overview. Journal of Autoimmunity 2018;95:144-58. [DOI: 10.1016/j.jaut.2018.10.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
20 Rizvi S, Yang JD, Gores GJ. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 2017;66:4-5. [PMID: 27587361 DOI: 10.1136/gutjnl-2016-312492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review. Clin Rev Allergy Immunol. 2020;58:134-149. [PMID: 31463807 DOI: 10.1007/s12016-019-08764-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
22 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Reference Citation Analysis]
23 Liwinski T, Zenouzi R, John C, Ehlken H, Rühlemann MC, Bang C, Groth S, Lieb W, Kantowski M, Andersen N, Schachschal G, Karlsen TH, Hov JR, Rösch T, Lohse AW, Heeren J, Franke A, Schramm C. Alterations of the bile microbiome in primary sclerosing cholangitis. Gut 2020;69:665-72. [PMID: 31243055 DOI: 10.1136/gutjnl-2019-318416] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
24 Hippchen T, Sauer P, Göppert B, Schirmacher P, Gotthardt DN, Weiss KH, Stremmel W, Rupp C. Association between serum IgG level and clinical course in primary sclerosing cholangitis. BMC Gastroenterol 2019;19:153. [PMID: 31455255 DOI: 10.1186/s12876-019-1075-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Wannhoff A, Gotthardt DN. Recent developments in the research on biomarkers of cholangiocarcinoma in primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol. 2018;pii:S2210-7401(18)30177-3. [PMID: 30266579 DOI: 10.1016/j.clinre.2018.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
26 Dhillon AK, Kremer AE, Kummen M, Boberg KM, Elferink RPO, Karlsen TH, Beuers U, Vesterhus M, Hov JR. Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. Sci Rep 2019;9:8450. [PMID: 31186435 DOI: 10.1038/s41598-019-44762-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Ferri PM, Simões E Silva AC, Campos Silva SL, de Aquino DJ, Fagundes ED, Marques de Miranda D, Ferreira AR. The Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in Childhood. Gastroenterol Res Pract 2016;2016:3905240. [PMID: 27882046 DOI: 10.1155/2016/3905240] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
28 Yue H, Liang W, Gu J, Zhao X, Zhang T, Qin X, Zhu G, Wu Z. Comparative transcriptome analysis to elucidate the therapeutic mechanism of colchicine against atrial fibrillation. Biomed Pharmacother 2019;119:109422. [PMID: 31514070 DOI: 10.1016/j.biopha.2019.109422] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
29 Fung BM, Tabibian JH. Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol. 2020;36:77-84. [PMID: 31850928 DOI: 10.1097/MOG.0000000000000616] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]